Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Global warming could be driving up women's cancer risk, find researchers
2.
Prostate cancer mortality is significantly reduced when docetaxel is used.
3.
A computer-aided diagnostic system for improved detection of breast cancer.
4.
Aster Whitefield Hospital, with 506 beds, opened.
5.
Cancer detection recovered following pandemic disruptions
1.
Intravenous Calcium for Reducing Blood Loss During Cesarean Delivery: A Review of Current Evidence
2.
Oncolytic Vaccinia Virus Immunotherapy: A New Frontier in GI Cancer Treatment
3.
Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer
4.
Beyond the Organs: Navigating the Era of Tissue-Agnostic Therapies in Modern Cancer Management
5.
Hemophilia: Pathophysiology, Genetics, and Treatment Advances
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part III
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Navigating the Complexities of Ph Negative ALL - Part XV
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge